The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids

Sebastian Prill, Andrea Caddeo, Guido Baselli, Oveis Jamialahmadi, Paola Dongiovanni, Raffaela Rametta, Kajsa P. Kanebratt, Arturo Pujia, Piero Pingitore, Rosellina Margherita Mancina, Daniel Lindén, Carl Whatling, Annika Janefeldt, Mikael Kozyra, Magnus Ingelman-Sundberg, Luca Valenti, Tommy B. Andersson, Stefano Romeo

Research output: Contribution to journalArticle

Abstract

There is a high unmet need for developing treatments for nonalcoholic fatty liver disease (NAFLD), for which there are no approved drugs today. Here, we used a human in vitro disease model to understand mechanisms linked to genetic risk variants associated with NAFLD. The model is based on 3D spheroids from primary human hepatocytes from five different donors. Across these donors, we observed highly reproducible differences in the extent of steatosis induction, demonstrating that inter-donor variability is reflected in the in vitro model. Importantly, our data indicates that the genetic variant TM6SF2 E167K, previously associated with increased risk for NAFLD, induces increased hepatocyte fat content by reducing APOB particle secretion. Finally, differences in gene expression pathways involved in cholesterol, fatty acid and glucose metabolism between wild type and TM6SF2 E167K mutation carriers (N = 125) were confirmed in the in vitro model. Our data suggest that the 3D in vitro spheroids can be used to investigate the mechanisms underlying the association of human genetic variants associated with NAFLD. This model may also be suitable to discover new treatments against NAFLD.

Original languageEnglish
Article number11585
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

Apolipoproteins B
Lipids
Liver
Hepatocytes
Medical Genetics
Fatty Acids
Fats
Cholesterol
Non-alcoholic Fatty Liver Disease
Gene Expression
Glucose
Mutation
In Vitro Techniques
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. / Prill, Sebastian; Caddeo, Andrea; Baselli, Guido; Jamialahmadi, Oveis; Dongiovanni, Paola; Rametta, Raffaela; Kanebratt, Kajsa P.; Pujia, Arturo; Pingitore, Piero; Mancina, Rosellina Margherita; Lindén, Daniel; Whatling, Carl; Janefeldt, Annika; Kozyra, Mikael; Ingelman-Sundberg, Magnus; Valenti, Luca; Andersson, Tommy B.; Romeo, Stefano.

In: Scientific Reports, Vol. 9, No. 1, 11585, 01.12.2019.

Research output: Contribution to journalArticle

Prill, S, Caddeo, A, Baselli, G, Jamialahmadi, O, Dongiovanni, P, Rametta, R, Kanebratt, KP, Pujia, A, Pingitore, P, Mancina, RM, Lindén, D, Whatling, C, Janefeldt, A, Kozyra, M, Ingelman-Sundberg, M, Valenti, L, Andersson, TB & Romeo, S 2019, 'The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids', Scientific Reports, vol. 9, no. 1, 11585. https://doi.org/10.1038/s41598-019-47737-w
Prill, Sebastian ; Caddeo, Andrea ; Baselli, Guido ; Jamialahmadi, Oveis ; Dongiovanni, Paola ; Rametta, Raffaela ; Kanebratt, Kajsa P. ; Pujia, Arturo ; Pingitore, Piero ; Mancina, Rosellina Margherita ; Lindén, Daniel ; Whatling, Carl ; Janefeldt, Annika ; Kozyra, Mikael ; Ingelman-Sundberg, Magnus ; Valenti, Luca ; Andersson, Tommy B. ; Romeo, Stefano. / The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{6e336e78a5fc4f3e8843088602ac0c10,
title = "The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids",
abstract = "There is a high unmet need for developing treatments for nonalcoholic fatty liver disease (NAFLD), for which there are no approved drugs today. Here, we used a human in vitro disease model to understand mechanisms linked to genetic risk variants associated with NAFLD. The model is based on 3D spheroids from primary human hepatocytes from five different donors. Across these donors, we observed highly reproducible differences in the extent of steatosis induction, demonstrating that inter-donor variability is reflected in the in vitro model. Importantly, our data indicates that the genetic variant TM6SF2 E167K, previously associated with increased risk for NAFLD, induces increased hepatocyte fat content by reducing APOB particle secretion. Finally, differences in gene expression pathways involved in cholesterol, fatty acid and glucose metabolism between wild type and TM6SF2 E167K mutation carriers (N = 125) were confirmed in the in vitro model. Our data suggest that the 3D in vitro spheroids can be used to investigate the mechanisms underlying the association of human genetic variants associated with NAFLD. This model may also be suitable to discover new treatments against NAFLD.",
author = "Sebastian Prill and Andrea Caddeo and Guido Baselli and Oveis Jamialahmadi and Paola Dongiovanni and Raffaela Rametta and Kanebratt, {Kajsa P.} and Arturo Pujia and Piero Pingitore and Mancina, {Rosellina Margherita} and Daniel Lind{\'e}n and Carl Whatling and Annika Janefeldt and Mikael Kozyra and Magnus Ingelman-Sundberg and Luca Valenti and Andersson, {Tommy B.} and Stefano Romeo",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-47737-w",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids

AU - Prill, Sebastian

AU - Caddeo, Andrea

AU - Baselli, Guido

AU - Jamialahmadi, Oveis

AU - Dongiovanni, Paola

AU - Rametta, Raffaela

AU - Kanebratt, Kajsa P.

AU - Pujia, Arturo

AU - Pingitore, Piero

AU - Mancina, Rosellina Margherita

AU - Lindén, Daniel

AU - Whatling, Carl

AU - Janefeldt, Annika

AU - Kozyra, Mikael

AU - Ingelman-Sundberg, Magnus

AU - Valenti, Luca

AU - Andersson, Tommy B.

AU - Romeo, Stefano

PY - 2019/12/1

Y1 - 2019/12/1

N2 - There is a high unmet need for developing treatments for nonalcoholic fatty liver disease (NAFLD), for which there are no approved drugs today. Here, we used a human in vitro disease model to understand mechanisms linked to genetic risk variants associated with NAFLD. The model is based on 3D spheroids from primary human hepatocytes from five different donors. Across these donors, we observed highly reproducible differences in the extent of steatosis induction, demonstrating that inter-donor variability is reflected in the in vitro model. Importantly, our data indicates that the genetic variant TM6SF2 E167K, previously associated with increased risk for NAFLD, induces increased hepatocyte fat content by reducing APOB particle secretion. Finally, differences in gene expression pathways involved in cholesterol, fatty acid and glucose metabolism between wild type and TM6SF2 E167K mutation carriers (N = 125) were confirmed in the in vitro model. Our data suggest that the 3D in vitro spheroids can be used to investigate the mechanisms underlying the association of human genetic variants associated with NAFLD. This model may also be suitable to discover new treatments against NAFLD.

AB - There is a high unmet need for developing treatments for nonalcoholic fatty liver disease (NAFLD), for which there are no approved drugs today. Here, we used a human in vitro disease model to understand mechanisms linked to genetic risk variants associated with NAFLD. The model is based on 3D spheroids from primary human hepatocytes from five different donors. Across these donors, we observed highly reproducible differences in the extent of steatosis induction, demonstrating that inter-donor variability is reflected in the in vitro model. Importantly, our data indicates that the genetic variant TM6SF2 E167K, previously associated with increased risk for NAFLD, induces increased hepatocyte fat content by reducing APOB particle secretion. Finally, differences in gene expression pathways involved in cholesterol, fatty acid and glucose metabolism between wild type and TM6SF2 E167K mutation carriers (N = 125) were confirmed in the in vitro model. Our data suggest that the 3D in vitro spheroids can be used to investigate the mechanisms underlying the association of human genetic variants associated with NAFLD. This model may also be suitable to discover new treatments against NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=85070894719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070894719&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-47737-w

DO - 10.1038/s41598-019-47737-w

M3 - Article

AN - SCOPUS:85070894719

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 11585

ER -